Anti-tumor protein isolated from ink of a sea slug destroys various kinds of cancers

11-Jul-2007

Celonic AG and APIT Laboratories GmbH have announced a commercial license agreement for of a new biopharmaceutical compound for the treatment of cancer. The anti-tumor protein, originally isolated from the defensive ink of a sea slug, attacks tumor cells in a threefold mechanism of action through the enzymatic production of reactive oxygen species and the deprivation of amino acids specifically required by tumor cells.

In vitro and in vivo experiments show that APIT efficiently destroys various kinds of cancers and could potentially also be used for the treatment of cancer becoming resistant to chemotherapy. This agreement grants Celonic the exclusive and worldwide rights for the development and marketing of the new pharmaceutical drug.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances